Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Acta Angiologica
MENU
Shortcuts Submit an article Author Guidelines Ahead Of Print Publisher's Jubilee Conference Abstracts Reviewers 2022

open access

Vol 28, No 1 (2022)
Research paper
Published online: 2022-05-02
View PDF Download PDF file
Get Citation

Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 as a diagnostic marker for acute ST-elevation myocardial infarction

waleed Osman1, Ahmed Elserafy2, Shadia Fathy1, Marwa Hegazy1, riham haroun1
DOI: 10.5603/AA.2022.0005
·
Acta Angiologica 2022;28(1):22-29.
Affiliations
  1. Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt
  2. Faculty of Medicine, Ain Shams University, Abbassia, Egypt

open access

Vol 28, No 1 (2022)
Original papers
Published online: 2022-05-02

Abstract

Background: ST-elevation myocardial infarction (STEMI) is a major cause of mortality and morbidity worldwide, but fast and reliable diagnosis can reduce mortality. Therefore, this study aimed to assess the diagnostic value of serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) among patients with acute STEMI, and also its importance to monitor the response to percutaneous coronary intervention (PCI). A total of 30 healthy subjects and 150 acute STEMI patients treated by PCI were enrolled into our study. Beside the routine lab work; serum sLOX-1 level was measured using commercial ELISA kit. Results: Our results revealed that the increased serum sLOX-1 level among patients with acute STEMI (112.79±10.76) than controls (47.75±12.87). After the treatment of acute STEMI patients with the primary PCI, the level of serum sLOX-1 was nonsigificantly decreased either after 12hrs (111.04±11.06) or 48hrs (110.31±11.24) from PCI management. Our results also showed that serum sLOX-1 level was positively correlated with cholesterol, LDL, troponin I, CK-MB, CRP, TG and VLDL. Results obtained from ROC curve analysis showed that serum sLOX-1 is an excellent biomarker for acute STEMI disease, its AUC is one with 100% sensitivity and specificity. Conclusions: Finally, from these results we can conclude that LOX-1 has a crucial role in the pathogenesis of acute STEMI; also, serum sLOX-1 could be a good diagnostic clinical biomarker for the detection of acute STEMI disease and to monitor the response to PCI.

Abstract

Background: ST-elevation myocardial infarction (STEMI) is a major cause of mortality and morbidity worldwide, but fast and reliable diagnosis can reduce mortality. Therefore, this study aimed to assess the diagnostic value of serum soluble lectin-like oxidized low-density lipoprotein receptor-1 (sLOX-1) among patients with acute STEMI, and also its importance to monitor the response to percutaneous coronary intervention (PCI). A total of 30 healthy subjects and 150 acute STEMI patients treated by PCI were enrolled into our study. Beside the routine lab work; serum sLOX-1 level was measured using commercial ELISA kit. Results: Our results revealed that the increased serum sLOX-1 level among patients with acute STEMI (112.79±10.76) than controls (47.75±12.87). After the treatment of acute STEMI patients with the primary PCI, the level of serum sLOX-1 was nonsigificantly decreased either after 12hrs (111.04±11.06) or 48hrs (110.31±11.24) from PCI management. Our results also showed that serum sLOX-1 level was positively correlated with cholesterol, LDL, troponin I, CK-MB, CRP, TG and VLDL. Results obtained from ROC curve analysis showed that serum sLOX-1 is an excellent biomarker for acute STEMI disease, its AUC is one with 100% sensitivity and specificity. Conclusions: Finally, from these results we can conclude that LOX-1 has a crucial role in the pathogenesis of acute STEMI; also, serum sLOX-1 could be a good diagnostic clinical biomarker for the detection of acute STEMI disease and to monitor the response to PCI.

Full Text:

View PDF Download PDF file
Get Citation

Keywords

Acute coronary syndrome (ACS); coronary heart disease; lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1); percutaneous coronary intervention (PCI); myocardial infarction (MI); ST-elevation myocardial infarction (STEMI).

About this article
Title

Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 as a diagnostic marker for acute ST-elevation myocardial infarction

Journal

Acta Angiologica

Issue

Vol 28, No 1 (2022)

Article type

Research paper

Pages

22-29

Published online

2022-05-02

Page views

4361

Article views/downloads

236

DOI

10.5603/AA.2022.0005

Bibliographic record

Acta Angiologica 2022;28(1):22-29.

Keywords

Acute coronary syndrome (ACS)
coronary heart disease
lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1)
percutaneous coronary intervention (PCI)
myocardial infarction (MI)
ST-elevation myocardial infarction (STEMI).

Authors

waleed Osman
Ahmed Elserafy
Shadia Fathy
Marwa Hegazy
riham haroun

References (30)
  1. - Singh A, Museedi AS, Grossman SA. Acute Coronary Syndrome. 2020 Jul 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 29083796.
  2. Liu Y, Huang Da, Li B, et al. Association between α1-antitrypsin and acute coronary syndrome. Exp Ther Med. 2020; 20(5): 119.
    CrossRefPubMed
  3. Akbar H, Foth C, Kahloon RA, Mountfort S. Acute ST Elevation Myocardial Infarction. 2020 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan–. PMID: 30335314.
  4. Henderson RA. Acute coronary syndrome: optimising management through risk assessment. Clin Med (Lond). 2013; 13(6): 602–606.
    CrossRefPubMed
  5. Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Intern Med. 2020; 59(3): 311–321.
    CrossRefPubMed
  6. Zhao ZW, Xu YW, Li SM, et al. Higher serum lectin-like oxidized low-density lipoprotein receptor-1 in patients with stable coronary artery disease is associated with major adverse cardiovascular events: A multicentre pilot study. Biochem Med (Zagreb). 2019; 29(1): 010705.
    CrossRefPubMed
  7. Pirillo A, Catapano AL. Soluble lectin-like oxidized low density lipoprotein receptor-1 as a biochemical marker for atherosclerosis-related diseases. Dis Markers. 2013; 35(5): 413–418.
    CrossRefPubMed
  8. Murase T, Kume N, Kataoka H, et al. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol. 2000; 20(3): 715–720.
    CrossRefPubMed
  9. Dey AK, Gaddipati R, Elnabawi YA, et al. Association Between Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 and Coronary Artery Disease in Psoriasis. JAMA Dermatol. 2020; 156(2): 151–157.
    CrossRefPubMed
  10. Aydin S, Ugur K, Aydin S, et al. Biomarkers in acute myocardial infarction: current perspectives. Vasc Health Risk Manag. 2019; 15: 1–10.
    CrossRefPubMed
  11. Mehta JL, Chen J, Hermonat PL, et al. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006; 69(1): 36–45.
    CrossRefPubMed
  12. Caglar IM, Ozde C, Biyik I, et al. Association between soluble lectin-like oxidized low-density lipoprotein receptor 1 levels and coronary slow flow phenomenon. Arch Med Sci. 2016; 12(1): 31–37.
    CrossRefPubMed
  13. Takanabe-Mori R, Ono K, Wada H, et al. Lectin-like oxidized low-density lipoprotein receptor-1 plays an important role in vascular inflammation in current smokers. J Atheroscler Thromb. 2013; 20(6): 585–590.
    CrossRefPubMed
  14. Tan KCB, Shiu SWM, Wong Y, et al. Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus. J Lipid Res. 2008; 49(7): 1438–1444.
    CrossRefPubMed
  15. Stankova TR, Delcheva GT, Maneva AI, et al. Serum Levels of Carbamylated LDL, Nitrotyrosine and Soluble Lectin-like Oxidized Low-density Lipoprotein Receptor-1 in Poorly Controlled Type 2 Diabetes Mellitus. Folia Med (Plovdiv). 2019; 61(3): 419–425.
    CrossRefPubMed
  16. Stankova T, Delcheva G, Maneva A, et al. Serum Levels of Carbamylated LDL and Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Are Associated with Coronary Artery Disease in Patients with Metabolic Syndrome. Medicina (Kaunas). 2019; 55(8).
    CrossRefPubMed
  17. Oncul M, Albayrak M, Sozer V, et al. Polycystic ovary syndrome and endothelial dysfunction: A potential role for soluble lectin-like oxidized low density lipoprotein receptor-1. Reprod Biol. 2020; 20(3): 396–401.
    CrossRefPubMed
  18. Ayashi S, Assareh AR, Jalali MT, et al. Role of antioxidant property of carvedilol in mild to moderate hypertensive patients: A prospective open-label study. Indian J Pharmacol. 2016; 48(4): 372–376.
    CrossRefPubMed
  19. Balin M, Celik A, Kobat MA, et al. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 levels predict percutaneous coronary intervention-related periprocedural myocardial infarction in stable patients undergoing elective native single-vessel PCI. J Thromb Thrombolysis. 2012; 34(4): 483–490.
    CrossRefPubMed
  20. Li Bo, Zhang Lh, Yang Xg, et al. Postprocedural serum sLOX-1 levels are associated with coronary in-stent restenosis in patients with stable coronary artery disease. Coron Artery Dis. 2011; 22(4): 259–263.
    CrossRefPubMed
  21. Kataoka H, Kume N, Miyamoto S, et al. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation. 1999; 99(24): 3110–3117.
    CrossRefPubMed
  22. Yokota C, Sawamura T, Watanabe M, et al. High Levels of Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Acute Stroke: An Age- and Sex-Matched Cross-Sectional Study. J Atheroscler Thromb. 2016; 23(10): 1222–1226.
    CrossRefPubMed
  23. Kobayashi N, Hata N, Kume N, et al. Soluble lectin-like oxidized low-density lipoprotein receptor-1 as an early biomarker for ST elevation myocardial infarction: time-dependent comparison with other biomarkers: time-dependent comparison with other biomarkers. Circ J. 2011; 75(6): 1433–1439.
    CrossRefPubMed
  24. Kume N, Mitsuoka H, Hayashida K, et al. Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome--comparison with other biomarkers. J Cardiol. 2010; 56(2): 159–165.
    CrossRefPubMed
  25. Kobayashi N, Hata N, Kume N, et al. Soluble lectin-like oxidized LDL receptor-1 and high-sensitivity troponin T as diagnostic biomarkers for acute coronary syndrome. Improved values with combination usage in emergency rooms. Circ J. 2011; 75(12): 2862–2871.
    CrossRefPubMed
  26. Wang X, Phillips MI, Mehta JL. LOX-1 and angiotensin receptors, and their interplay. Cardiovasc Drugs Ther. 2011; 25(5): 401–417.
    CrossRefPubMed
  27. Wang X, Khaidakov M, Ding Z, et al. Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) and cardiac fibroblast growth. Hypertension. 2012; 60(6): 1437–1442.
    CrossRefPubMed
  28. Liang YQ, Kakino A, Matsuzaka Y, et al. LOX-1 (Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1) Deletion Has Protective Effects on Stroke in the Genetic Background of Stroke-Prone Spontaneously Hypertensive Rat. Stroke. 2020; 51(6): 1835–1843.
    CrossRefPubMed
  29. Li X, Tang X, Liu Bo, et al. LOX-1 Deletion Attenuates Myocardial Fibrosis in the Aged Mice, Particularly Those With Hypertension. Front Cardiovasc Med. 2021; 8: 736215.
    CrossRefPubMed
  30. Luo P, Yan M, Frohlich ED, et al. Novel concepts in the genesis of hypertension: role of LOX-1. Cardiovasc Drugs Ther. 2011; 25(5): 441–449.
    CrossRefPubMed

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl